The relationship between durvalumab and Infinifer

Durvalumab/Infinifer (Durvalumab) is an immune checkpoint inhibitor that belongs to the PD-L1 inhibitor category and is widely used in the immunotherapy of various tumors. Its mechanism of action is to relieve the suppression of the immune system by tumor cells and activate the anti-tumor effect of T cells by targeting the PD-1/PD-L1 pathway, thereby enhancing the body's immune system to recognize and eliminate tumor cells. The drug is mainly used to treat non-small cell lung cancer (NSCLC), urothelial cancer (especially bladder cancer) and other types of malignant tumors. It restores the normal function of the immune system, allowing immune cells to effectively recognize and attack tumor cells.

In the Chinese market, durvalumab is registered under the trade name Yinfeifan. Therefore, durvalumab and Infinifer are actually the same drug, just with different names. Durvalumab is developed and produced by AstraZeneca. Its mechanism of action, efficacy and side effects are consistent with Durvalumab in overseas markets. The trade name Infinifer is mainly used for sales and promotion in the Chinese market, so that Chinese patients can purchase this drug locally.

One of the characteristics of durvalumab is that it activates the body's immune system through immune checkpoint inhibition. This method is different from traditional chemotherapy and radiotherapy. It does not directly kill tumor cells, but recognizes and eliminates tumors by activating the body's immune cells. PD-L1 is a tumor cell surface protein that inhibits the activity of immune cells by binding to the PD-1 receptor in the immune system and prevents the immune system from attacking tumor cells. By inhibiting the function of PD-L1, durvalumab can restore the function of immune cells, thereby effectively enhancing the anti-tumor immune response.

Compared with other immune checkpoint inhibitors (such as nivolumab), the target of durvalumab isPD-L1, which is commonly expressed in multiple tumor types. Therefore, durvalumab has shown better efficacy in treating different types of cancer.

Reference materials:https://www.imfinzi.com/